Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 4, 2009, Pages 669-676

  Vaughan, Brigette ^a   Fegert, Joerg ^b   Kratochvil, Christopher J ^a  

^a Department of Psychiatry ^*  (United States)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

ADHD; Atomoxetine; Pharmacotherapy; Stimulant

Indexed keywords

AMPHETAMINE; ATOMOXETINE; FLUOXETINE; METHYLPHENIDATE; PAROXETINE; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT; PROPYLAMINE;

ABDOMINAL PAIN; ANOREXIA; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COMORBIDITY; COUGHING; DECREASED APPETITE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; GILLES DE LA TOURETTE SYNDROME; GROUPS BY AGE; HEADACHE; HEART RATE; HUMAN; INSOMNIA; LIVER TOXICITY; LOW DRUG DOSE; MAJOR DEPRESSION; MENTAL INSTABILITY; NAUSEA; NOCTURNAL ENURESIS; OPPOSITIONAL DEFIANT DISORDER; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; REVIEW; SEPARATION ANXIETY; SIDE EFFECT; SINGLE DRUG DOSE; SOCIAL PHOBIA; SOMNOLENCE; SUICIDE ATTEMPT; TIC; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT; ADOLESCENT; ADULT; CHILD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CONTROLLED CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PROPYLAMINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65649121932     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902762873     Document Type: Review

References (48)

1. Lavigne JV, Gibbons RD, Christoffel KK, et al. Prevalence rates and correlates of psychiatric disorders among preschool children. J Am Acad Child Adolesc Psychiatry 1996;35:204-214 (Pubitemid 26039700)
2. Biederman J, Spencer TJ. Psychopharmacological interventions. Child Adolesc Psychiatr Clin N Am 2008;17:439-58, xi (Pubitemid 351258358)
3. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. J Pediatr 2001;108:1033-1044 • AAP Practice Guideline for treating ADHD in school-aged children.
4. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(2 Suppl):26-49
5. Pliszka SR, Liotti M, Bailey BY, et al. Electrophysiological effects of stimulant treatment on inhibitory control in children with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17:356-366 (Pubitemid 47067959)
6. Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/ hyperactivity disorder: overview of the evidence. Pediatrics 2005;115:749-757 (Pubitemid 43843150)
7. Madaan V, Kinnan S, Daughton J, Kratochvil CJ. Innovations and recent trends in the treatment of ADHD. Expert Rev Neurother 2006;6:1375-1385 (Pubitemid 44596133)
8. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-921 •• AACAP practice parameter for the assessment and treatment of children and adolescents with ADHD.
9. Winterstein AG, Gerhard T, Shuster J, et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in medicaid database. Ann Pharmacother 2008;42:24-31
10. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:50-54
11. Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995;34:1140-1146
12. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001;158:1067-1074 (Pubitemid 32623110)
13. Cohen DJ, Riddle MA, Leckman JF. Pharmacotherapy of Tourette's syndrome and associated disorders. Psychiatr Clin North Am 1992;15:109-129
14. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996;35:1314-1321 (Pubitemid 26327705)
15. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158:282-288 (Pubitemid 32116526)
16. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155:693-695 (Pubitemid 28225414)
17. Eli Lilly and company. Strattera package insert. Indianapolis, 2005
18. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27:699-711 (Pubitemid 35335888)
19. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD rating scale-IV: checklists, norms, and clinical interpretations. New York: Guilford Press, 1998
20. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001;108:E83
21. Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 2005;44:915-924 (Pubitemid 41193203)
22. Belle DJ, Ernest CS, Sauer JM, et al. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 2002;42:1219-1227 (Pubitemid 35205057)
23. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004;114:1-8
24. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112-120 (Pubitemid 36126473)
25. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-1901 (Pubitemid 35283256)
26. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63:1140-1147 (Pubitemid 36084059)
27. Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005;44:647-655 (Pubitemid 40875359)
28. Kratochvil CJ, Michelson D, Newcorn JH, et al. High-dose atomoxetine treatment of adhd in youths with limited response to standard doses. J Am Acad Child Adolesc Psychiatry 2007;46:1128-1137 (Pubitemid 47295924)
29. Newcorn JH, Michelson D, Kratochvil CJ, et al. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder. Pediatrics 2006;118:1701-1706 (Pubitemid 46397544)
30. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008;165:721-730 • Comparison of atomoxetine and OROS methylphenidate. (Pubitemid 351810541)
31. Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005;9:275-289 (Pubitemid 41551759)
32. Adler LA, Spencer TJ, Williams DW, et al. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 2008;12:248-253
33. Wilens TE, Kratochvil C, Newcorn JH, Gao H. Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry 2006;45:149-157
34. Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr 2006;149:112-119 (Pubitemid 44081915)
35. Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL. Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy. Child Adolesc Psychiatry Ment Health 2008;2:25
36. Kratochvil CJ, Vaughan BS, Mayfield-Jorgensen ML, et al. A pilot study of atomoxetine in young children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17:175-185 (Pubitemid 46828913)
37. Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001;40:147-158 (Pubitemid 32111018)
38. Biederman J, Spencer TJ, Newcorn JH, et al. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. Psychopharmacology (Berl) 2007;190:31-41 (Pubitemid 44885341)
39. Spencer TJ, Sallee FR, Gilbert DL, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord 2008;11:470-481
40. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007;46:1119-1127 (Pubitemid 47295923)
41. Bangs ME, Emslie GJ, Spencer TJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/ hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 2007;17:407-420 (Pubitemid 47422213)
42. Sumner CR, Schuh KJ, Sutton VK, et al. Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis. J Child Adolesc Psychopharmacol 2006;16:699-711 (Pubitemid 46175426)
43. Spencer TJ, Newcorn JH, Kratochvil CJ, et al. Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/ hyperactivity disorder. Pediatrics 2005;116:74-80
44. Spencer TJ, Kratochvil CJ, Sangal RB, et al. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol 2007;17:689-700 • 5-year data on the effects of atomoxetine on growth in children with ADHD. (Pubitemid 350058975)
45. Reith DM, Edmonds L. Assessing the role of drugs in suicidal ideation and suicidality. CNS Drugs 2007;21:463-472 (Pubitemid 46849182)
46. Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008;31:345-354
47. Perrin JM, Friedman RA, Knilans TK. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 2008;122:451-453
48. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006;15:476-495